CYP19A1 and serous adenocarcinoma: Retrospective series have suggested activity of aromatase inhibition and antiangiogenic therapy in low-grade serous carcinoma.17, 18, 19, 20, 21 However, no positive randomised study of any therapy in low-grade serous carcinoma has been reported to date.